Amarin says post hoc REDUCE-IT analysis shows Icosapent Ethyl cardiovascular benefit persists after treatment stops

PUBT · 2d ago
Amarin says post hoc REDUCE-IT analysis shows Icosapent Ethyl cardiovascular benefit persists after treatment stops
  • Amarin flagged a new post hoc REDUCE-IT “legacy” analysis presented at the European Society of Cardiology Congress 2026.
  • The study suggests patients who stayed on icosapent ethyl long enough kept cardiovascular protection for years, even after stopping treatment.
  • Benefits appeared strongest in highly adherent patients, supporting the commercial case for sustained use in high-risk populations.
  • The analysis also indicates earlier gains may persist in secondary prevention patients who discontinued therapy during trial follow-up.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amarin Corporation plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608280815PRIMZONEFULLFEED9816526) on August 28, 2026, and is solely responsible for the information contained therein.